Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Lexaria Bioscience (Nasdaq: LEXX) has been granted two new patents from the United States Patent and Trademark Office for its DehydraTECH enhanced processing technology in epilepsy treatment. These represent the company's 5th and 6th US patents in its patent family #24, 'Compositions and Methods for Treating Epilepsy,' bringing Lexaria's total granted patents to 48.
The patents, set to expire in 2043 unless extended, build upon previous research demonstrating that DehydraTECH-CBD could mitigate epileptic seizures in rodents and showed superior bloodstream absorption compared to Epidiolex, a commercial cannabinoid-based anti-seizure medication.
Lexaria Bioscience (Nasdaq: LEXX) ha ricevuto due nuovi brevetti dall'Ufficio Brevetti e Marchi degli Stati Uniti per la sua tecnologia di lavorazione avanzata DehydraTECH nel trattamento dell'epilessia. Questi rappresentano il 5° e il 6° brevetto statunitense della famiglia di brevetti #24, 'Composizioni e Metodi per il Trattamento dell'Epilessia,' portando il totale dei brevetti concessi a Lexaria a 48.
I brevetti, che scadranno nel 2043 a meno di una proroga, si basano su ricerche precedenti che dimostrano che DehydraTECH-CBD potrebbe attenuare le crisi epilettiche nei roditori e ha mostrato un'assorbimento nel flusso sanguigno superiore rispetto all'Epidiolex, un farmaco commerciale a base di cannabinoidi per il trattamento delle crisi.
Lexaria Bioscience (Nasdaq: LEXX) ha recibido dos nuevas patentes de la Oficina de Patentes y Marcas de los Estados Unidos para su tecnología de procesamiento mejorada DehydraTECH en el tratamiento de la epilepsia. Estas representan la 5ª y 6ª patentes estadounidenses de la familia de patentes #24, 'Composiciones y Métodos para el Tratamiento de la Epilepsia,' aumentando el total de patentes concedidas a Lexaria a 48.
Las patentes, que expiran en 2043 a menos que se extiendan, se basan en investigaciones previas que demuestran que DehydraTECH-CBD podría mitigar las convulsiones epilépticas en roedores y mostró una absorción en el torrente sanguíneo superior en comparación con Epidiolex, un medicamento comercial basado en cannabinoides para las convulsiones.
Lexaria Bioscience (Nasdaq: LEXX)는 미국 특허상표청으로부터 DehydraTECH 향상된 가공 기술에 대한 두 개의 새로운 특허를 받았습니다. 이는 '간질 치료를 위한 조성물 및 방법'이라는 특허 가족 #24의 미국 특허 5번 및 6번에 해당하며, Lexaria가 보유한 총 특허 수를 48건으로 증가시킵니다.
특허는 연장되지 않는 한 2043년에 만료되며, DehydraTECH-CBD가 설치류의 간질 발작을 완화할 수 있음을 입증한 이전 연구를 기반으로 하며, 상업용 칸나비노이드 기반 항발작 약물인 Epidiolex에 비해 혈액 흡수율이 우수한 것으로 나타났습니다.
Lexaria Bioscience (Nasdaq: LEXX) a obtenu deux nouveaux brevets de l'Office américain des brevets et des marques pour sa technologie de traitement améliorée DehydraTECH dans le traitement de l'épilepsie. Cela représente le 5e et le 6e brevet américain de la famille de brevets #24, 'Compositions et Méthodes pour le Traitement de l'Épilepsie,' portant le total des brevets accordés à Lexaria à 48.
Les brevets, qui expireront en 2043 sauf prolongation, s'appuient sur des recherches antérieures montrant que DehydraTECH-CBD pourrait atténuer les crises épileptiques chez les rongeurs et montrait une absorption supérieure dans le flux sanguin par rapport à Epidiolex, un médicament anti-crise à base de cannabinoïdes.
Lexaria Bioscience (Nasdaq: LEXX) hat vom US-Patent- und Markenamt zwei neue Patente für seine DehydraTECH-verbesserte Verarbeitungstechnologie zur Behandlung von Epilepsie erhalten. Diese stellen das 5. und 6. US-Patent in der Patentfamilie #24, 'Zusammensetzungen und Methoden zur Behandlung von Epilepsie,' dar und erhöhen die Gesamtzahl der erteilten Patente von Lexaria auf 48.
Die Patente, die im Jahr 2043 ablaufen, es sei denn, sie werden verlängert, bauen auf früheren Forschungen auf, die zeigen, dass DehydraTECH-CBD epileptische Anfälle bei Nagetieren lindern könnte und eine überlegene Blutabsorption im Vergleich zu Epidiolex, einem kommerziellen cannabinoidbasierten Antikonvulsivum, aufwies.
- Received two new US patents for epilepsy treatment technology
- Patents extend protection until 2043
- Previous research showed superior absorption compared to existing medication (Epidiolex)
- Total patent portfolio expanded to 48 granted patents
- None.
Insights
The granting of two new DehydraTECH patents for epilepsy treatment marks a significant milestone in Lexaria's intellectual property strategy. These are the 5th and 6th US patents in their epilepsy-focused patent family, creating a robust protective moat around their technology through 2043.
The expanded patent claims are particularly valuable given the $6.1 billion global epilepsy therapeutics market. The technology's demonstrated superior absorption compared to Epidiolex - a FDA-approved CBD-based epilepsy medication with over
The timing is opportune as major pharmaceutical companies are increasingly seeking novel drug delivery technologies that can enhance the bioavailability of existing treatments. With 48 total granted patents, Lexaria has built a comprehensive IP portfolio that could command significant licensing fees or partnership terms. The extended patent protection through 2043 provides a lengthy exclusivity window that enhances negotiating leverage with potential partners.
However, investors should note that while patent protection is crucial, commercial success will ultimately depend on clinical validation and regulatory approval. The company will need to demonstrate DehydraTECH's safety and efficacy in human trials to fully capitalize on this expanded IP protection.
Additions broaden DehydraTECH patent suite for Epilepsy
KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy.
"We are thrilled to have received broadened claims related to our proprietary DehydraTECH™ technology for the treatment of epilepsy," said Rich Christopher, CEO of Lexaria. "Each of our patent awards enhances our ability to reach commercial criticality while providing enhanced value to our potential pharmaceutical partners and, ultimately, to patients."
Lexaria has received its 5th and 6th US patents granted in its patent family #24, Compositions and Methods for Treating Epilepsy. These patents complement earlier research which indicated that DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex®. The new patents expire in 2043, if not extended, and increase Lexaria's granted patent total to 48.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What new patents did Lexaria (LEXX) receive in February 2024?
How long will Lexaria's (LEXX) new epilepsy treatment patents last?
How does Lexaria's DehydraTECH-CBD compare to Epidiolex?
How many total patents does Lexaria (LEXX) now hold?
